The global hospital acquired pneumonia drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to accelerate the growth of the market include increasing risk factors with longer hospital stays. Pneumonia is a leading cause of death across the globe with a fatality rate of 4-10%. Hospital-acquired pneumonia is the most common form among the others and it has a huge impact on the lifestyle of the patient. Further, it is associated with a high mortality rate and requires immediate medical intervention. Owing to this, there is a huge demand for pharmacological intervention for effective management of the disease. According to Infectious Control and Epidemiology, the overall incidence in the US is 1.6% and represents 3.63 per 1000 patients. Increasing prevalence among the healthcare settings led to the potential growth of the market.

Hospital-acquired pneumonia is acquired by patients after they are being admitted to the hospital for more than 48 hours. The public healthcare system is facing a tough challenge in the form of hospital-acquired pneumonia as it is the second most common hospital-acquired infection. Pneumonia causes agitation of the lungs and mainly affects the alveoli which are microscopic air sacs. Primary causes of hospital-acquired pneumonia are bacteria or viral infections and they can be differentiated based on how the infection was acquired by the patient. In order to maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. For instance, in July 2019, Bayer Healthcare partnered with Cubist pharmaceutical Inc. and co-developed Sivextro, an antibiotic for hospital-acquired pneumonia treatment.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Merck & Co., Inc., Pfizer Inc, and GlaxoSmithKline plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hospital Acquired Pneumonia Drugs Market Report by Segment

By Type

• Antibacterial

• Antiviral

• Antifungal

By Application

• Hospitals

• Clinics

• Others

Global Hospital Acquired Pneumonia Drugs Market by Region